CStone Pharmaceuticals (HKG:2616)
Hong Kong · Delayed Price · Currency is HKD 6.07
-0.10 (-1.62%)
Sep 10, 2026, 11:59 AM HKT
CStone Pharmaceuticals Revenue
CStone Pharmaceuticals had revenue of 205.10M CNY in the half year ending June 30, 2026, a decrease of -19.30%. This brings the company's revenue in the last twelve months to 425.23M, up 110.00% year-over-year. In the year 2025, CStone Pharmaceuticals had annual revenue of 269.58M, down -33.80%.
Revenue (ttm)
425.23M CNY
Revenue Growth
+110.00%
P/S Ratio
20.02
Revenue / Employee
4.17M CNY
Employees
102
Market Cap
9.83B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 269.58M | -137.62M | -33.80% |
| Dec 31, 2024 | 407.21M | -56.64M | -12.21% |
| Dec 31, 2023 | 463.84M | -17.52M | -3.64% |
| Dec 31, 2022 | 481.36M | 237.65M | 97.51% |
| Dec 31, 2021 | 243.72M | -795.11M | -76.54% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Everest Medicines | 2.78B |
| HBM Holdings | 1.40B |
| Ascentage Pharma Group International | 741.90M |
| Alphamab Oncology | 598.06M |
| Suzhou Ribo Life Science | 536.18M |
| Nanjing Leads Biolabs | 246.16M |
| GenFleet Therapeutics (Shanghai) | 144.96M |
| Ascletis Pharma | 1.09M |
CStone Pharmaceuticals News
- 13 days ago - CStone Pharmaceuticals Earnings release: H1 2026 - Filings
- 13 days ago - CStone Pharmaceuticals Slides: H1 2026 - Filings
- 2 months ago - CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand - PRNewsWire
- 3 months ago - ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept - PRNewsWire
- 4 months ago - CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3) - PRNewsWire
- 5 months ago - CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0 - PRNewsWire
- 5 months ago - CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) - PRNewsWire
- 5 months ago - CStone Pharmaceuticals Earnings release: H2 2025 - Filings